Abstract
Bacteriophages are considered to be the small viruses possessing an important role to infect bacteria’s tending to replicate therefore maintaining the environment of bacteria existence in equilibrium. Bacteriophages were considered to be potent therapeutics for the treatment against the bacterial infections in humans. Initially, bacteriophages were implemented for the treatment of intestinal diseases and later, its implications were carried further for during the surgical practice in the twentieth century. But the role of antibiotics has pushed down the importance of bacteriophage but the hasty increase of multi-drug resistant bacteria has portrayed the importance of phage therapy which is a potential substitute to antibiotics. Recently, various results have been recorded for the successful rates of the bacteriophages in the treatment of various infections in clinical cases and clinical trials. Due to growing importance in combating bacterial infection to diminish the antibiotic resistance, the bacteriophage are proposed as a powerful therapeutic agent in wide range of applied areas such as medicine, biotechnology, agriculture, biosensor, veterinary and even more. Thus, we introduce this chapter to brief the concept of phage, phage history, and phage biology with highlights of phage therapy, phage engineering, as well as phage applications including the future of phage.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abedon ST (2019) Phage-antibiotic combination treatments: antagonistic impacts of antibiotics on the pharmacodynamics of phage therapy? Antibiotics (Basel) 8(4):pii: E182. https://doi.org/10.3390/antibiotics8040182
Abedon ST, Thomas-Abedon C, Thomas A, Mazure H (2011a) Bacteriophage prehistory: is or is not Hankin, 1896, a phage reference? Bacteriophage 1(3):174–178. https://doi.org/10.4161/bact.1.3.16591
Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM (2011b) Phage treatment of human infections. Bacteriophage 1(2):66–85. https://doi.org/10.4161/bact.1.2.15845
Abedon ST, Garcia P, Mullany P, Aminov R (2017a) Editorial: phage therapy: past, present and future. Front Microbiol 8:981. https://doi.org/10.3389/fmicb.2017.00981
Abedon ST, García P, Mullany P, Aminov R (2017b) Phage therapy: past, present and future. Front Microbiol 8:981. https://doi.org/10.3389/fmicb.2017.00981
Ackermann HW (2003) Bacteriophage observations and evolution. Res Microbiol 154(4):245–251. https://doi.org/10.1016/S0923-2508(03)00067-6
Ackermann HW (2009) Phage classification and characterization. Methods Mol Biol 501:127–140. https://doi.org/10.1007/978-1-60327-164-6_13
Ackermann HW (2011) The first phage electron micrographs. Bacteriophage 1(4):225–227. https://doi.org/10.4161/bact.1.4.17280
Aghebati-Maleki L, Bakhshinejad B, Baradaran B, Motallebnezhad M, Aghebati-Maleki A, Nickho H, Yousefi M, Majidi J (2016) Phage display as a promising approach for vaccine development. J Biomed Sci 23(1):66. https://doi.org/10.1186/s12929-016-0285-9
Aiewsakun P, Adriaenssens EM, Lavigne R, Kropinski AM, Simmonds P (2018) Evaluation of the genomic diversity of viruses infecting bacteria, archaea and eukaryotes using a common bioinformatic platform: steps towards a unified taxonomy. J Gen Virol 99:1331–1343. https://doi.org/10.1099/jgv.0.001110
Altamirano FL, Barr JJ (2019) Phage therapy in the postantibiotic era. Clin Microbiol Rev 32(2):pii: e00066-18. https://doi.org/10.1128/CMR.00066-18
Bardell D (1982) An 1898 report by Gamaleya for a lytic agent specific for Bacillus anthracis. J Hist Med Allied Sci 37(2):222–225. https://doi.org/10.1093/jhmas/xxxvii.2.222
Bazan J, Całkosiński I, Gamian A (2012) Phage display—A powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications. Hum Vaccin Immunother 8(12):1817–1828. https://doi.org/10.4161/hv.21703
Bertozzi Silva J, Storms Z, Sauvageau D (2016) Host receptors for bacteriophage adsorption. FEMS Microbiol Lett 363(4):pii: fnw002. https://doi.org/10.1093/femsle/fnw002
Bhattarai SR, Yoo SY, Lee SW, Dean D (2012) Engineered phage-based therapeutic materials inhibit Chlamydia trachomatis intracellular infection. Biomaterials 33(20):5166–5174. https://doi.org/10.1016/j.biomaterials.2012.03.054
Breitbart M, Rohwer F (2005) Here a virus, there a virus, everywhere the same virus? Trends Microbiol 13:278–284. https://doi.org/10.1016/j.tim.2005.04.003
Breitbart M, Wegley L, Leeds S, Schoenfeld T, Rohwer F (2004) Phage community dynamics in hot springs. Appl Environ Microbiol 70(3):1633–1640. https://doi.org/10.1128/aem.70.3.1633-1640.2004
Brown R, Lengeling A, Wang B (2017) Phage engineering: how advances in molecular biology and synthetic biology are being utilized to enhance the therapeutic potential of bacteriophages. Quant Biol 5(1):42–54. https://doi.org/10.1007/s40484-017-0094-5
Campbell A (2003) The future of bacteriophage biology. Nat Rev Genet 4(6):471–477. https://doi.org/10.1038/nrg1089
Carlton RM (1999) Phage therapy: past history and future prospects. Arch Immunol Ther Exp 47(5):267–274
Casjens SR, Hendrix RW (2015) Bacteriophage lambda: early pioneer and still relevant. Virology 479:310–330. https://doi.org/10.1016/j.virol.2015.02.010
Chan BK, Abedon ST, Loc-Carrillo C (2013) Phage cocktails and the future of phage therapy. Future Microbiol 8(6):769–783. https://doi.org/10.2217/fmb.13.47
Chen Y, Batra H, Dong J, Chen C, Rao VB, Tao P (2019) Genetic engineering of bacteriophages against infectious diseases. Front Microbiol 10:954. https://doi.org/10.3389/fmicb.2019.00954
Chibani-Chennoufi S, Bruttin A, Dillmann ML, Brüssow H (2004) Phage-host interaction: an ecological perspective. J Bacteriol 186(12):3677–3686. https://doi.org/10.1128/JB.186.12.3677-3686.2004
Cisek AA, Dąbrowska I, Gregorczyk KP, Wyżewski Z (2017) Phage therapy in bacterial infections treatment: one hundred years after the discovery of bacteriophages. Curr Microbiol 74(2):277–283. https://doi.org/10.1007/s00284-016-1166-x
Clokie MR, Millard AD, Letarov AV, Heaphy S (2011) Phages in nature. Bacteriophage 1:31–45. https://doi.org/10.4161/bact.1.1.14942
Cormack BP, Valdivia RH, Falkow S (1996) FACS-optimized mutants of the green fluorescent protein (GFP). Gene 173:33–38. https://doi.org/10.1016/0378-1119(95)00685-0
Criscuolo E, Spadini S, Lamanna J, Ferro M, Burioni R (2017) Bacteriophages and their immunological applications against infectious threats. J Immunol Res 2017:3780697. https://doi.org/10.1155/2017/3780697
Dąbrowska K (2019) Phage therapy: what factors shape phage pharmacokinetics and bioavailability? Systematic and critical review. Med Res Rev 39(5):2000–2025. https://doi.org/10.1002/med.21572
Debarbieux L, Pirnay JP, Verbeken G, De Vos D, Merabishvili M, Huys I, Patey O, Schoonjans D, Vaneechoutte M, Zizi M, Rohde C (2016) A bacteriophage journey at the European Medicines Agency. FEMS Microbiol Lett 363(2):fnv225. https://doi.org/10.1093/femsle/fnv225
Debarbieux L, Fischer M, Quax TEF (2017) Viruses of microbes. Viruses 9:263. https://doi.org/10.3390/v9090263
Deng X, Wang L, You X, Dai P, Zeng Y (2018) Advances in the T7 phage display system. Mol Med Rep 17(1):714–720. https://doi.org/10.3892/mmr.2017.7994
Derda R, Lockett MR, Tang SK, Fuller RC, Maxwell EJ, Breiten B, Cuddemi CA, Ozdogan A, Whitesides GM (2013) Filter-based assay for Escherichia coli in aqueous samples using bacteriophage-based amplification. Anal Chem 85(15):7213–7220. https://doi.org/10.1021/ac400961b
Deresinski S (2009) Bacteriophage therapy: exploiting smaller fleas. Clin Infect Dis 48(8):1096–1101. https://doi.org/10.1086/597405
d’Hérelle F (2007) On an invisible microbe antagonistic toward dysenteric bacilli: brief note by Mr. F. D’Herelle, presented by Mr. Roux. 1917. Res Microbiol 158(7):553
Dixon B (2004) New dawn for phage therapy. Lancet Infect Dis 4(3):186. https://doi.org/10.1016/S1473-3099(04)00951-X
Doetschman T, Georgieva T (2017) Gene editing with CRISPR/Cas9 RNA-directed nuclease. Circ Res 120(5):876–894. https://doi.org/10.1161/CIRCRESAHA.116.309727
Domingo-Calap P, Delgado-Martínez J (2018) Bacteriophages: protagonists of a post-antibiotic era. Antibiotics (Basel) 7(3):pii: E66. https://doi.org/10.3390/antibiotics7030066
Doss J, Culbertson K, Hahn D, Camacho J, Barekzi N (2017) A review of phage therapy against bacterial pathogens of aquatic and terrestrial organisms. Viruses 9(3):50. https://doi.org/10.3390/v9030050
Drulis-Kawa Z, Majkowska-Skrobek G, Maciejewska B, Delattre AS, Lavigne R (2012) Learning from bacteriophages-advantages and limitations of phage and phage-encoded protein applications. Curr Protein Pept Sci 13(8):699–722. https://doi.org/10.2174/138920312804871193
Du Toit A (2017) The language of phages. Nat Rev Microbiol 15:135. https://doi.org/10.1038/nrmicro.2017.8
Easwaran M, Ahn J (2019) Application of bacteriophages in organic farm animal production. Safety Pract Organic Food 1:365–375. https://doi.org/10.1016/B978-0-12-812060-6.00018-0
Efimov VP, Nepluev IV, Mesyanzhinov VV (1995) Bacteriophage T4 as a surface display vector. Virus Genes 10(2):173–177. https://doi.org/10.1007/bf01702598
Eiserling FA (1979) Bacteriophage structure. In: Fraenkel-Conrat H, Wagner RR (eds) Comprehensive virology volume 13: structure and assembly, Comprehensive virology. Springer, Boston. https://doi.org/10.1007/978-1-4684-3453-8_8
Erez Z, Steinberger-Levy I, Shamir M et al (2017) Communication between viruses guides lysis–lysogeny decisions. Nature 541:488–493. https://doi.org/10.1038/nature21049
Fair RJ, Tor Y (2014) Antibiotics and bacterial resistance in the 21st century. Perspect Med Chem 6:25–64. https://doi.org/10.4137/PMC.S14459
Fauconnier A (2019) Phage therapy regulation: from night to dawn. Viruses 11(4):352. https://doi.org/10.3390/v11040352
Gamage LN, Ellis J, Hayes S (2009) Immunogenicity of bacteriophage lambda particles displaying porcine Circovirus 2 (PCV2) capsid protein epitopes. Vaccine 27(47):6595–6604. https://doi.org/10.1016/j.vaccine.2009.08.019
Górski A, Międzybrodzki R, Borysowski J, Dąbrowska K, Wierzbicki P, Ohams M, Korczak-Kowalska G, Olszowska-Zaremba N, Łusiak-Szelachowska M, Kłak M, Jończyk E (2012) Phage as a modulator of immune responses: practical implications for phage therapy. Adv Virus Res 83:41–71. https://doi.org/10.1016/B978-0-12-394438-2.00002-5
Hao M, Cui Y, Qu X (2018) Analysis of CRISPR-Cas system in Streptococcus thermophilus and its application. Front Microbiol 9:257. https://doi.org/10.3389/fmicb.2018.00257
Haq IU, Chaudhry WN, Akhtar MN, Andleeb S, Qadri I (2012) Bacteriophages and their implications on future biotechnology: a review. Virol J 9:9. https://doi.org/10.1186/1743-422X-9-9
Harada LK, Silva EC, Campos WF, Del Fiol FS, Vila M, Dąbrowska K, Krylov VN, Balcão VM (2018) Biotechnological applications of bacteriophages: state of the art. Microbiol Res 212–213:38–58. https://doi.org/10.1016/j.micres.2018.04.007
Hatoum-Aslan A (2018) Phage genetic engineering using CRISPR-Cas systems. Viruses 10(6):pii: E335. https://doi.org/10.3390/v10060335
Henein A (2013) What are the limitations on the wider therapeutic use of phage? Bacteriophage 3(2):e24872
Henry M, Debarbieux L (2012) Tools from viruses: bacteriophage successes and beyond. Virology 434(2):151–161. https://doi.org/10.1016/j.virol.2012.09.017
Hess KL, Jewell CM (2019) Phage display as a tool for vaccine and immunotherapy development. Bioeng Transl Med 5. https://doi.org/10.1002/btm2.10142
Hesse S, Adhya S (2019) Phage therapy in the twenty-first century: facing the decline of the antibiotic era; is it finally time for the age of the phage? Annu Rev Microbiol 73:155
Howard-Varona C, Hargreaves KR, Abedon ST, Sullivan MB (2017a) Lysogeny in nature: mechanisms, impact and ecology of temperate phages. ISME J 11(7):1511
Howard-Varona C, Hargreaves K, Abedon S et al (2017b) Lysogeny in nature: mechanisms, impact and ecology of temperate phages. ISME J 11:1511–1520. https://doi.org/10.1038/ismej.2017.16
Hyman P, Abedon ST (2010) Bacteriophage host range and bacterial resistance. Adv Appl Microbiol 70:217–248. https://doi.org/10.1016/S0065-2164(10)70007-1
Jault P, Leclerc T, Jennes S, Pirnay JP, Que YA, Resch G, Rousseau AF, Ravat F, Carsin H, Le Floch R, Schaal JV (2019) Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis 19(1):35–45. https://doi.org/10.1016/S1473-3099(18)30482-1
Jayaraman R (2008) Seymour benzer and T4 rII. Resonance 13:898–908. https://doi.org/10.1007/s12045-008-0098-6
Kara R (2018) Bacteriophage. https://www.britannica.com/science/bacteriophage. October 12 2018
Karen S (2018) Lytic vs lysogenic – understanding bacteriophage life cycles. https://www.technologynetworks.com/immunology/articles/lytic-vs-lysogenic-understanding-bacteriophage-life-cycles-308094. August 28 2018
Karen DW (2019) Building better bacteriophage with biofoundries to combat antibiotic-resistant bacteria, December 27, 2019
Keen EC, Adhya SL (2015) Phage therapy: current research and applications. Clin Infect Dis 61(1):141–142
Kilcher S, Loessner MJ (2019) Engineering bacteriophages as versatile biologics. Trends Microbiol 27(4):355–367
Kilcher S, Studer P, Muessner C, Klumpp J, Loessner MJ (2018) Cross-genus rebooting of custom-made, synthetic bacteriophage genomes in L-form bacteria. Proc Natl Acad Sci U S A 115(3):567–572. https://doi.org/10.1073/pnas.1714658115
Kim M, Ryu S (2013) Antirepression system associated with the life cycle switch in the temperate podoviridae phage SPC32H. J Virol 87(21):11775–11786. https://doi.org/10.1128/JVI.02173-13
Koivunen E, Arap W, Rajotte D, Lahdenranta J, Pasqualini R (1999) Identification of receptor ligands with phage display peptide libraries. J Nucl Med 40(5):883–888
Kortright KE, Chan BK, Koff JL, Turner PE (2019) Phage therapy: a renewed approach to combat antibiotic-resistant bacteria. Cell Host Microbe 25(2):219–232
Krylov V, Shaburova O, Krylov S, Pleteneva E (2012) A genetic approach to the development of new therapeutic phages to fight pseudomonas aeruginosa in wound infections. Viruses 5(1):15–53. https://doi.org/10.3390/v5010015
Kutateladze M, Adamia R (2008) Phage therapy experience at the Eliava Institute. Med Mal Infect 38(8):426–430. https://doi.org/10.1016/j.medmal.2008.06.023
Lin DM, Koskella B, Lin HC (2017) Phage therapy: an alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther 8(3):162
Loc-Carrillo C, Abedon ST (2011) Pros and cons of phage therapy. Bacteriophage 1(2):111–114. https://doi.org/10.4161/bact.1.2.14590
Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, Darnell J (2000) Viruses: structure, function, and uses. In: Molecular cell biology, 4th edn. WH Freeman, New York
Loessner MJ, Rudolf M, Scherer S (1997) Evaluation of luciferase reporter bacteriophage A511::luxAB for detection of Listeria monocytogenes in contaminated foods. Appl Environ Microbiol 63(8):2961–2965
Löwy I (2010) Martin Arrowsmith’s clinical trial: scientific precision and heroic medicine. J R Soc Med 103(11):461–466
Luria SE, Anderson TF (1942) The identification and characterization of bacteriophages with the electron microscope. Proc Natl Acad Sci U S A 28(4):127–130.1. https://doi.org/10.1073/pnas.28.4.127
Ly-Chatain MH (2014) The factors affecting effectiveness of treatment in phages therapy. Front Microbiol 5:51. https://doi.org/10.3389/fmicb.2014.00051
Makarova KS, Wolf YI, Iranzo J et al (2019) Evolutionary classification of CRISPR–Cas systems: a burst of class 2 and derived variants. Nat Rev Microbiol 18:67–83. https://doi.org/10.1038/s41579-019-0299-x
Marinelli LJ, Piuri M, Swigoňová Z, Balachandran A, Oldfield LM, van Kessel JC, Hatfull GF (2008) BRED: a simple and powerful tool for constructing mutant and recombinant bacteriophage genomes. PLoS One 3(12):e3957. https://doi.org/10.1371/journal.pone.0003957
Marinelli LJ, Piuri M, Hatfull GF (2019) Genetic manipulation of lytic bacteriophages with BRED: bacteriophage recombineering of electroporated DNA. Methods Mol Biol 1898:69–80. https://doi.org/10.1007/978-1-4939-8940-9_6
Mark T (2019) Are phages the wave of the future? Using viruses to treat bacterial diseases. https://www.biospace.com/article/are-phages-the-wave-of-the-future-using-viruses-to-treat-bacterial-diseases/ May 16, 2019
Matsuzaki S, Uchiyama J (2019) Phage pharmacokinetics: relationship with administration route. In: Phage therapy: a practical approach. Springer, Cham, pp 43–57. https://doi.org/10.1007/978-3-030-26736-0_2
Matsuzaki S, Rashel M, Uchiyama J, Sakurai S, Ujihara T, Kuroda M, Ikeuchi M, Tani T, Fujieda M, Wakiguchi H, Imai S (2005) Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. J Infect Chemother 11(5):211–219. https://doi.org/10.1007/s10156-005-0408-9
McDonald ND, Regmi A, Morreale DP, Borowski JD, Boyd EF (2019) CRISPR-Cas systems are present predominantly on mobile genetic elements in Vibrio species. BMC Genomics 20(1):105. https://doi.org/10.1186/s12864-019-5439-1
McGrath S, Fitzgerald GF, van Sinderen D (2004) The impact of bacteriophage genomics. Curr Opin Biotechnol 15(2):94–99
Molek P, Strukelj B, Bratkovic T (2011) Peptide phage display as a tool for drug discovery: targeting membrane receptors. Molecules 16(1):857–887. https://doi.org/10.3390/molecules16010857
Monk AB, Rees CD, Barrow P, Hagens S, Harper DR (2010) Bacteriophage applications: where are we now? Lett Appl Microbiol 51:363–369
Morozova VV, Vlassov VV, Tikunova NV (2018) Applications of bacteriophages in the treatment of localized infections in humans. Front Microbiol 9:1696. https://doi.org/10.3389/fmicb.2018.01696
Muzard J, Platt M, Lee GU (2012) M13 bacteriophage-activated superparamagnetic beads for affinity separation. Small 8(15):2403–2411. https://doi.org/10.1002/smll.201200099
Nair A, Khairnar K (2019) Genetically engineered phages for therapeutics: proceed with caution. Nat Med 25(7):1028. https://doi.org/10.1038/s41591-019-0506-3
Ofir G, Sorek R (2018) Contemporary phage biology: from classic models to new insights. Cell 172:1260–1270
Oh D, Qi J, Han B, Zhang G, Carney TJ, Ohmura J, Zhang Y, Shao-Horn Y, Belcher AM (2014) M13 virus-directed synthesis of nanostructured metal oxides for lithium-oxygen batteries. Nano Lett 14(8):4837–4845. https://doi.org/10.1021/nl502078m
O’Sullivan L, Buttimer C, McAuliffe O, Bolton D, Coffey A (2016) Bacteriophage-based tools: recent advances and novel applications. F1000Res 5:2782. https://doi.org/10.12688/f1000research.9705.1
Pande J, Szewczyk MM, Grover AK (2010) Phage display: concept, innovations, applications and future. Biotechnol Adv 28(6):849–858. https://doi.org/10.1016/j.biotechadv.2010.07.004
Parfitt T (2005) Georgia an unlikely stronghold for bacteriophage therapy. Lancet 365(9478):2166–2167. https://doi.org/10.1016/S0140-6736(05)66759-1
Pelfrene E, Willebrand E, Cavaleiro Sanches A, Sebris Z, Cavaleri M (2016) Bacteriophage therapy: a regulatory perspective. J Antimicrob Chemother 71(8):2071–2074. https://doi.org/10.1093/jac/dkw083.v
Pierrel J (2012) An RNA phage lab: MS2 in Walter Fiers’ laboratory of molecular biology in Ghent, from genetic code to gene and genome, 1963–1976. J Hist Biol 45(1):109–138. https://doi.org/10.1007/s10739-010-9267-z
Pines G, Freed EF, Winkler JD, Gill RT (2015) Bacterial recombineering: genome engineering via phage-based homologous recombination. ACS Synth Biol 4(11):1176–1185. https://doi.org/10.1021/acssynbio.5b00009s
Pires DP, Cleto S, Sillankorva S, Azeredo J, Lu TK (2016) Genetically engineered phages: a review of advances over the last decade. Microbiol Mol Biol Rev 80(3):523–543. https://doi.org/10.1128/MMBR.00069-15
Pirnay JP, Verbeken G, Rose T, Jennes S, Zizi M, Huys I, Lavigne R, Merabishvili M, Vaneechoutte M, Buckling A, De Vos D (2012) Introducing yesterday’s phage therapy in today’s medicine. Futur Virol 7(4):379–390. https://doi.org/10.2217/fvl.12.24
Prasad BV, Schmid MF (2012) Principles of virus structural organization. Adv Exp Med Biol 726:17–47. https://doi.org/10.1007/978-1-4614-0980-9_3
Prigent M, Leroy M, Confalonieri F, Dutertre M, DuBow MS (2005) A diversity of bacteriophage forms and genomes can be isolated from the surface sands of the Sahara Desert. Extremophiles 9(4):289–296. https://doi.org/10.1007/s00792-005-0444-5
Principi N, Silvestri E, Esposito S (2019) Advantages and limitations of bacteriophages for the treatment of bacterial infections. Front Pharmacol 10:513. https://doi.org/10.3389/fphar.2019.00513
Roshan N (2018) The future is phage? https://sfam.org.uk/resources/the-future-is-phage.html
Ross A, Ward S, Hyman P (2016) More is better: selecting for broad host range bacteriophages. Front Microbiol 7:1352. https://doi.org/10.3389/fmicb.2016.01352
Rowley MJ, O’Connor K, Wijeyewickrema L (2004) Phage display for epitope determination: a paradigm for identifying receptor-ligand interactions. Biotechnol Annu Rev 10:151–188. https://doi.org/10.1016/S1387-2656(04)10006-9
Ryan EM, Gorman SP, Donnelly RF, Gilmore BF (2011) Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy. J Pharm Pharmacol 63(10):1253–1264. https://doi.org/10.1111/j.2042-7158.2011.01324.x
Salmond GP, Fineran PC (2015) A century of the phage: past, present and future. Nat Rev Microbiol 13:777. https://doi.org/10.1038/nrmicro3564
Sanger F, Coulson AR (1975) A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. J Mol Biol 94(3):441–448. https://doi.org/10.1016/0022-2836(75)90213-2
Säwström C, Lisle J, Anesio AM, Priscu JC, Laybourn-Parry J (2008) Bacteriophage in polar inland waters. Extremophiles 12(2):167–175. https://doi.org/10.1007/s00792-007-0134-6
Schofield DA, Molineux IJ, Westwater C (2009) Diagnostic bioluminescent phage for detection of Yersinia pestis. J Clin Microbiol 47(12):3887–3894. https://doi.org/10.1128/JCM.01533-09
Schofield DA, Bull CT, Rubio I, Wechter WP, Westwater C, Molineux IJ (2012) Development of an engineered bioluminescent reporter phage for detection of bacterial blight of crucifers. Appl Environ Microbiol 78(10):3592–3598. https://doi.org/10.1128/AEM.00252-12
Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L, Barr JJ, Reed SL, Rohwer F, Benler S, Segall AM (2017) Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother 61(10):e00954-17. https://doi.org/10.1128/AAC.00954-17
Semler DD, Lynch KH, Dennis JJ (2012) The promise of bacteriophage therapy for Burkholderia cepacia complex respiratory infections. Front Cell Infect Microbiol 1:27. https://doi.org/10.3389/fcimb.2011.00027
Sharma S, Chatterjee S, Datta S, Prasad R, Dubey D, Prasad RK, Vairale MG (2017) Bacteriophages and its applications: an overview. Folia Microbiol 62:17–55. https://doi.org/10.1007/s12223-016-0471-x
Shivachandra SB, Rao M, Janosi L, Sathaliyawala T, Matyas GR, Alving CR, Leppla SH, Rao VB (2006) In vitro binding of anthrax protective antigen on bacteriophage T4 capsid surface through hoc–capsid interactions: a strategy for efficient display of large full-length proteins. Virology 345(1):190–198. https://doi.org/10.1016/j.virol.2005.10.037
Sillankorva S, Pospiech H, Azeredo J, Neubauer P (2007) Biofilm control with T7 phage. J Biotechnol 131(2):S252. https://doi.org/10.1016/j.jbiotec.2007.07.458
Sioud M (2019) Phage display libraries: from binders to targeted drug delivery and human therapeutics. Mol Biotechnol 61(4):286–303. https://doi.org/10.1007/s12033-019-00156-8
Skurnik M, Strauch E (2006) Phage therapy: facts and fiction. Int J Med Microbiol 296(1):5–14. https://doi.org/10.1016/j.ijmm.2005.09.002
Smith GP (2019) Phage display: simple evolution in a Petri Dish (Nobel lecture). Angew Chem Int Ed 58:14428–14437. https://doi.org/10.1002/anie.201908308
Sousa JAMd, Rocha EPC (2019) Environmental structure drives resistance to phages and antibiotics during phage therapy and to invading lysogens during colonisation. Sci Rep 9:3149. https://doi.org/10.1038/s41598-019-39773-3
Speck P, Smithyman A (2016) Safety and efficacy of phage therapy via the intravenous route. FEMS Microbiol Lett 363(3):pii: fnv242. https://doi.org/10.1093/femsle/fnv242
Stanford K, McAllister TA, Niu YD, Stephens TP, Mazzocco A, Waddell TE, Johnson RP (2010) Oral delivery systems for encapsulated bacteriophages targeted at Escherichia coli O157:H7 in feedlot cattle. J Food Prot 73(7):1304–1312. https://doi.org/10.4315/0362-028x-73.7.1304
Sternberg N, Hoess RH (1995) Display of peptides and proteins on the surface of bacteriophage lambda. Proc Natl Acad Sci U S A 92(5):1609–1613. https://doi.org/10.1073/pnas.92.5.1609
Stone E, Campbell K, Grant I, McAuliffe O (2019) Understanding and exploiting phage-host interactions. Viruses 11(6):pii: E567. https://doi.org/10.3390/v11060567
Sulakvelidze A, Alavidze Z, Morris JG (2001) Bacteriophage therapy. Antimicrob Agents Chemother 45:649–659. https://doi.org/10.1128/AAC.45.3.649-659.2001
Summers WC (2012) The strange history of phage therapy. Bacteriophage 2(2):130–133
Svircev A, Roach D, Castle A (2018) Framing the future with bacteriophages in agriculture. Viruses 10(5):pii: E218. https://doi.org/10.3390/v10050218
Tagliaferri TL, Jansen M, Horz HP (2019) Fighting pathogenic bacteria on two fronts: phages and antibiotics as combined strategy. Front Cell Infect Microbiol 9:22. https://doi.org/10.3389/fcimb.2019.00022
The Nobel Prize in Physiology or Medicine (1969) Nobel Prize.org. Nobel Media AB. https://www.nobelprize.org/prizes/medicine/1969/summary
Tolstoy I, Kropinski AM, Brister JR (2018) Bacteriophage taxonomy: an evolving discipline. Methods Mol Biol 1693:57–71. https://doi.org/10.1007/978-1-4939-7395-8_6
Tornetta M, Baker S, Whitaker B, Lu J, Chen Q, Pisors E, Shi L, Luo J, Sweet R, Tsui P (2010) Antibody fab display and selection through fusion to the pIX coat protein of filamentous phage. J Immunol Methods 360(1–2):39–46. https://doi.org/10.1016/j.jim.2010.06.001
Twort FW (1915) An investigation on the nature of ultra-microscopic viruses. Lancet 2:1241–1243. https://doi.org/10.1016/S0140-6736(01)20383-3
Underwood SL, Foto A, Ray AF, Nelms AE, Kennedy KL, Hartley SG, Ryals LM, Gurung C, D’Angelo WA, Pope WH, Mavrodi DV (2019) Discovery and characterization of bacteriophage LuckyBarnes. Microbiol Resour Announc 8(25):pii: e00330-19. https://doi.org/10.1128/MRA.00330-19
Van Belleghem J, Dąbrowska K, Vaneechoutte M, Barr J, Bollyky P (2018) Interactions between bacteriophage, bacteria, and the mammalian immune system. Viruses 11(1):pii: E10. https://doi.org/10.3390/v11010010
Van der Merwe RG, Van Helden PD, Warren RM, Sampson SL, van Pittius NG (2014) Phage-based detection of bacterial pathogens. Analyst 139(11):2617–2626. https://doi.org/10.1039/c4an00208c
Van Duin J (1988) Single-stranded RNA bacteriophages. In: Calendar R (ed) The bacteriophages, The viruses. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-5424-6_4
Voelker R (2019) FDA approves bacteriophage trial. JAMA 321(7):638. https://doi.org/10.1001/jama.2019.0510
Waldor MK, Mekalanos JJ (1996) Lysogenic conversion by a filamentous phage encoding cholera toxin. Science 272(5270):1910–1914. https://doi.org/10.1126/science.272.5270.1910
White HE, Orlova EV (2019) Bacteriophages: their structural organisation and function. In: Bacteriophages-biology and applications. IntechOpen. https://doi.org/10.5772/intechopen.85484
Wienhold SM, Lienau J, Witzenrath M (2019) Towards inhaled phage therapy in Western Europe. Viruses 11:295
Williamson SJ, Paul JH (2004) Nutrient stimulation of lytic phage production in bacterial populations of the Gulf of Mexico. Aquat Microb Ecol 36(1):9–17. https://doi.org/10.3354/ame036009
Wittebole X, De Roock S, Opal SM (2014) A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence 5(1):226–235. https://doi.org/10.4161/viru.25991
Xu H, Bao X, Wang Y, Xu Y, Deng B, Lu Y, Hou J (2018) Engineering T7 bacteriophage as a potential DNA vaccine targeting delivery vector. Virol J 15(1):49. https://doi.org/10.1186/s12985-018-0955-1
Yehl K, Lemire S, Yang AC, Ando H, Mimee M, Torres MD, de la Fuente-Nunez C, Lu TK (2019) Engineering phage host-range and suppressing bacterial resistance through phage tail fiber mutagenesis. Cell 179(2):459–469.e9. https://doi.org/10.1016/j.cell.2019.09.015
Yosef I, Manor M, Kiro R, Qimron U (2015) Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria. Proc Natl Acad Sci 112(23):7267–7272. https://doi.org/10.1073/pnas.1500107112
Young RY (1992) Bacteriophage lysis: mechanism and regulation. Microbiol Rev 56(3):430–481
Zhang QG, Buckling A (2012) Phages limit the evolution of bacterial antibiotic resistance in experimental microcosms. Evol Appl 5(6):575–582. https://doi.org/10.1111/j.1752-4571.2011.00236.x
Zirpel NK, Arslan T, Lee H (2015) Engineering filamentous bacteriophages for enhanced gold binding and metallization properties. J Colloid Interface Sci 454:80–88. https://doi.org/10.1016/j.jcis.2015.05.006
Zschach H, Joensen K, Lindhard B, Lund O, Goderdzishvili M, Chkonia I, Jgenti G, Kvatadze N, Alavidze Z, Kutter E, Hasman H (2015) What can we learn from a metagenomic analysis of a Georgian bacteriophage cocktail? Viruses 7(12):6570–6589. https://doi.org/10.3390/v7122958
Acknowledgments
SKS, UP, and MA gratefully acknowledge the Alagappa University for providing research facility. SKS thank MHRD RUSA – Phase 2.0 (grant sanctioned vide letter No. F. 24-51 / 2014 – U, Policy (TNMulti-Gen), Dept. of Edn. Govt. of India, Dt. 09.10.2018), DST-PURSE 2nd Phase Programme Order No. SR/PURSE Phase 2/38 (G dated 21.02.2017 and FIST (SR/FST/LSI – 667/2016) for providing the financial assistance. UP thank to Indian Council of Medical Research (ISRM/11/(19)/2017,dated:09.08.2018) for providing ICMR-SRF (Senior Research Fellowship). MA thanks UGC for providing RGNF fellowship award no: F1-17/2016-17/RGNF-2015-17-SC-TAM-18759.
Conflict of Interest
The Author(s) declare that there is no conflict of interest.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Panwar, U., Aarthy, M., Singh, S.K. (2020). Bacteriophage as a Therapeutic Agent to Combat Bacterial Infection: A Journey from History to Application. In: Witzany, G. (eds) Biocommunication of Phages. Springer, Cham. https://doi.org/10.1007/978-3-030-45885-0_17
Download citation
DOI: https://doi.org/10.1007/978-3-030-45885-0_17
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-45884-3
Online ISBN: 978-3-030-45885-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)